Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.32 |
| ▸ | GNRHR | P30968 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27213468 | 0.91 | ALPL (0.33) | AKR1B1GNRHRALDH1A1MAPTPKM | |
| SCHEMBL20543580 | 0.89 | MAPT (0.35) | ALDH1A1MAPTPKMHTTKMT2A | |
| SCHEMBL21879011 | 0.88 | NPC1 (0.34) | ALDH1A1MAPTADORA2AADORA2BADORA1 | |
| SCHEMBL27213497 | 0.86 | PLA2G7 (0.34) | AKR1B1ALDH1A1MAPTHTTKMT2A | |
| SCHEMBL20543671 | 0.85 | GNRHR (0.34) | GNRHRALDH1A1MAPTPKMHTT | |
| SCHEMBL30110624 | 0.85 | GNRHR (0.34) | GNRHRALDH1A1MAPTPKMHTT | |
| SCHEMBL27213526 | 0.85 | ALPL (0.34) | AKR1B1PDE3BPDE3A | |
| SCHEMBL25760197 | 0.83 | CASR (0.32) | GNRHRALDH1A1PKMKMT2A | |
| SCHEMBL25760181 | 0.83 | LTB4R (0.32) | GNRHRALDH1A1MAPTPKMKMT2A | |
| SCHEMBL21879010 | 0.83 | GNRHR (0.34) | GNRHRKMT2APDE3BPDE3AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120051474-A | Coelenterazine analogs | 普罗美加公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20240150363-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2024-05-09 | — | — | US | disclosed |
| WO-2024081914-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION (US) | 2024-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150363-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, AADAC | AKR1B1 4310/4885GNRHR 1136/4885ALDH1A1 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.